Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone long-term safety in children with disruptive behavior disorders
NCT00236470Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2002
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of risperidone in conduct disorder (CD), Disruptive behavior disorders (DBD), sponsored by Johnson & Johnson. Started Jan 2002; status: completed.
02
Drugs
risperidone
03
Conditions
conduct disorder (CD)Disruptive behavior disorders (DBD)
Beyond the preview
Go deeper on NCT00236470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236470.